<p>以超過 8000 億美元的市值，<strong>禮來</strong>(LLY 0.70%) 是全球最大的製藥公司。這在很大程度上要歸功於類胰高血糖素-1(GLP-1) 激動劑的崛起，如 Mounjaro 和 Zepbound，這些產品正在為公司帶來新一波增長。</p>
<p>在過去的 12 個月裏，禮來的股價飆升了 58%，幾乎是 <strong>標普 500 指數</strong> 和 <strong>納斯達克綜合指數</strong> 漲幅的兩倍。鑑於其股價飆升，一些投資者可能認為股票分拆可能即將到來。雖然這種可能性存在，但我認為這種情況不太可能發生。自 1997 年 10 月以來，禮來就沒有進行過股票分拆。</p>
<p>相反，我認為公司將會提高其股息。讓我們深入瞭解一下禮來的股息歷史，並探討為什麼我認為在年底之前可能會有一次提高。</p>
<h2>禮來的股息歷史</h2>
<p>在其公司網站上，禮來的財務記錄可以追溯到 1972 年。當時，禮來每股支付的季度股息僅為 0.01 美元。如今，投資者每股持有的股息為 1.30 美元（或每年 5.20 美元）。</p>
<p>儘管看到禮來在其歷史上不斷提高股息是件好事，但情況並非總是如此。請注意下面的圖表，從 2009 年到 2014 年，禮來的股息保持不變。然而，公司從 2015 年開始穩步提高股息，這一趨勢一直延續至今。</p>
<p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/a49ddf68012adcc94b68f8bff4fd858c.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/a49ddf68012adcc94b68f8bff4fd858c.png"/></p>
<p>由 YCharts 提供的 LLY 股息數據</p>
<p>2015 年股息上調背後的原因之一可能是禮來的糖尿病藥物 Trulicity 獲得了 2014 年底美國食品和藥物管理局（FDA）的批准。</p>
<p>儘管像 Zepbound 和 Mounjaro 這樣的 GLP-1 藥物目前是禮來最新的風向標，但公司對其癌症藥物 Verzenio 的擴大適應症以及最近獲得的治療阿爾茨海默病的批准信號表明未來還有進一步增長。</p>
<p>基於這些原因，我認為禮來不僅僅是在維持其股息，而是會再次提高股息。</p>
<h2>禮來歷史上何時提高股息？</h2>
<p>儘管禮來從 2015 年開始一直在穩步提高股息，但投資者應該瞭解一些關於這些支付時間表的細節。自那時以來，禮來每年都會在 12 月宣佈提高股息支付，而除息日定在 2 月中旬。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy83OTExMzkvZ2V0dHlpbWFnZXMtMTkyNDc2NTkxMS5qcGcmdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy83OTExMzkvZ2V0dHlpbWFnZXMtMTkyNDc2NTkxMS5qcGcmdz03MDA"/></p>
<p>圖片來源：Getty Images。</p>
<h2>結論</h2>
<p>雖然我不能確定禮來是否會在即將到來的 12 月再次提高股息，但歷史趨勢支持我的觀點。如果你認為禮來將在 12 月宣佈提高股息，那麼你可能希望在除息日之前（可能在 2 月某個時候）購入股票。</p>
<p>禮來在 GLP-1 治療、治療阿爾茨海默病甚至在人工智能領域有着巨大潛力。但更重要的是，投資禮來不僅僅是投資其暢銷藥品。該公司為投資者提供了一個獨特的價值主張，您將接觸到醫療領域的幾個前沿領域，同時還能獲得股息。</p>
<p>我認為禮來是一個低調的 passsive income 機會，現在是購買股票的絕佳時機，無論 12 月是否再次發生股息提高。</p>

禮來

<p>禮來（LLY）是全球最大的製藥公司，市值超過 2000 億美元，其增長主要來自 GLP-1 激動劑如 Mounjaro 和 Zepbound。過去一年，其股價上漲了 58%，引發了關於股票分拆的猜測，但這被認為是不太可能的。相反，人們預計會增加股息，延續了在 12 月提高股息的歷史趨勢。投資者被鼓勵考慮購買股票以獲取 passsive income，因為禮來在包括糖尿病和阿爾茨海默病治療在內的各個醫療領域都處於增長的位置</p>

<p>With a market capitalization of over $800 billion, <strong>Eli Lilly</strong>(LLY 0.70%) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.</p>
<div class="lb-trans"><p>以超過 8000 億美元的市值，<strong>禮來</strong>(LLY 0.70%) 是全球最大的製藥公司。這在很大程度上要歸功於類胰高血糖素-1(GLP-1) 激動劑的崛起，如 Mounjaro 和 Zepbound，這些產品正在為公司帶來新一波增長。</p>
</div><p>Over the past 12 months, its shares have soared 58% -- nearly double the gains generated from the <strong>S&amp;P 500</strong> and <strong>Nasdaq Composite</strong>. Given its soaring share price, some investors might think a stock split could be on the horizon. While this is possible, I see it as unlikely. Lilly hasn't split its stock since October 1997.</p>
<div class="lb-trans"><p>在過去的 12 個月裏，禮來的股價飆升了 58%，幾乎是 <strong>標普 500 指數</strong> 和 <strong>納斯達克綜合指數</strong> 漲幅的兩倍。鑑於其股價飆升，一些投資者可能認為股票分拆可能即將到來。雖然這種可能性存在，但我認為這種情況不太可能發生。自 1997 年 10 月以來，禮來就沒有進行過股票分拆。</p>
</div><p>Instead, I think the company is going to raise its dividend. Let's dig into Lilly's dividend history, and explore why I think a raise could come before year-end.</p>
<div class="lb-trans"><p>相反，我認為公司將會提高其股息。讓我們深入瞭解一下禮來的股息歷史，並探討為什麼我認為在年底之前可能會有一次提高。</p>
</div><h2>Eli Lilly's dividend history</h2>
<div class="lb-trans"><h2>禮來的股息歷史</h2>
</div><p>On its corporate website, Eli Lilly's financial records date back to 1972. Back then, Lilly paid a modest quarterly dividend of just $0.01 per share. Today, investors receive quarterly dividend payments of $1.30 (or $5.20 per year) for each share they own.</p>
<div class="lb-trans"><p>在其公司網站上，禮來的財務記錄可以追溯到 1972 年。當時，禮來每股支付的季度股息僅為 0.01 美元。如今，投資者每股持有的股息為 1.30 美元（或每年 5.20 美元）。</p>
</div><p>While it's nice to see that Lilly has raised its dividend throughout its history, that hasn't always been the case. Note in the graph below how between 2009 and 2014 Lilly's dividend stayed flat. However, the company began to steadily raise its dividend starting in 2015, and this is a theme that has remained to today.</p>
<div class="lb-trans"><p>儘管看到禮來在其歷史上不斷提高股息是件好事，但情況並非總是如此。請注意下面的圖表，從 2009 年到 2014 年，禮來的股息保持不變。然而，公司從 2015 年開始穩步提高股息，這一趨勢一直延續至今。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/a49ddf68012adcc94b68f8bff4fd858c.png" alt="" original-src="https://media.ycharts.com/charts/a49ddf68012adcc94b68f8bff4fd858c.png"/></p>
<p>LLY Dividend data by YCharts</p>
<div class="lb-trans"><p>由 YCharts 提供的 LLY 股息數據</p>
</div><p>One of the reasons behind the dividend hike in 2015 could have been the approval of Lilly's diabetes medication Trulicity, which got the nod from the Food and Drug Administration (FDA) in late 2014.</p>
<div class="lb-trans"><p>2015 年股息上調背後的原因之一可能是禮來的糖尿病藥物 Trulicity 獲得了 2014 年底美國食品和藥物管理局（FDA）的批准。</p>
</div><p>While GLP-1 medicines such as Zepbound and Mounjaro are currently Lilly's newest bellwethers, the company's expanded indication for its cancer drug, Verzenio, plus its recent approval for its Alzheimer's treatment signal further growth ahead.</p>
<div class="lb-trans"><p>儘管像 Zepbound 和 Mounjaro 這樣的 GLP-1 藥物目前是禮來最新的風向標，但公司對其癌症藥物 Verzenio 的擴大適應症以及最近獲得的治療阿爾茨海默病的批准信號表明未來還有進一步增長。</p>
</div><p>For these reasons, I think Lilly is positioned for more than just maintaining its dividend, but raising it again.</p>
<div class="lb-trans"><p>基於這些原因，我認為禮來不僅僅是在維持其股息，而是會再次提高股息。</p>
</div><h2>When does Elil Lilly historically raise its dividend?</h2>
<div class="lb-trans"><h2>禮來歷史上何時提高股息？</h2>
</div><p>Although Lilly started consistently raising its dividend in 2015, investors should be aware of some details around the schedule of these payments. Every year since then, Lilly announced a hike to its dividend payment in December with an ex-dividend date slotted for mid-February.</p>
<div class="lb-trans"><p>儘管禮來從 2015 年開始一直在穩步提高股息，但投資者應該瞭解一些關於這些支付時間表的細節。自那時以來，禮來每年都會在 12 月宣佈提高股息支付，而除息日定在 2 月中旬。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy83OTExMzkvZ2V0dHlpbWFnZXMtMTkyNDc2NTkxMS5qcGcmdz03MDA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F791139%2Fgettyimages-1924765911.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><h2>The bottom line</h2>
<div class="lb-trans"><h2>結論</h2>
</div><p>While I can't say for certain that Lilly will raise its dividend again this upcoming December, historical trends are on my side. If you do think Lilly is going to announce a dividend hike in December, then you may want to scoop up shares before the ex-dividend date (likely to be sometime in February).</p>
<div class="lb-trans"><p>雖然我不能確定禮來是否會在即將到來的 12 月再次提高股息，但歷史趨勢支持我的觀點。如果你認為禮來將在 12 月宣佈提高股息，那麼你可能希望在除息日之前（可能在 2 月某個時候）購入股票。</p>
</div><p>Lilly has enormous potential between GLP-1 treatments, treating Alzheimer's disease, and even longer-term bets in artificial intelligence. But the bigger idea here is that there is more to investing in Lilly than just its blockbuster drugs. The company offers investors a unique value proposition in that you're exposed to several cutting-edge areas in the healthcare realm, while also collecting a dividend.</p>
<div class="lb-trans"><p>禮來在 GLP-1 治療、治療阿爾茨海默病甚至在人工智能領域有着巨大潛力。但更重要的是，投資禮來不僅僅是投資其暢銷藥品。該公司為投資者提供了一個獨特的價值主張，您將接觸到醫療領域的幾個前沿領域，同時還能獲得股息。</p>
</div><p>I see Lilly as an under-the-radar passive income opportunity and think now is as good a time as ever to buy shares, whether a dividend hike occurs again in December or not.</p>
<div class="lb-trans"><p>我認為禮來是一個低調的 passsive income 機會，現在是購買股票的絕佳時機，無論 12 月是否再次發生股息提高。</p>
</div>

預測：禮來股票接下來的走勢（提示：不是股票拆分）